open access

Vol 67, No 1 (2017)
Other materials agreed with the Editors
Published online: 2017-08-24
Get Citation

Should local treatment of breast ductal carcinoma in situ be the same as the treatment of early invasive breast cancer

Sylwia Grodecka-Gazdecka
DOI: 10.5603/NJO.2017.0012
·
Nowotwory. Journal of Oncology 2017;67(1):74-78.

open access

Vol 67, No 1 (2017)
Short review
Published online: 2017-08-24

Abstract

Heterogenicity of breast ductal carcinoma in situ gives rise to opposing proposals concerning its treatment — ranging from attempts to recommend the watch and wait strategy in low risk forms ending with the currently binding stan­dards of treatment of DCIS in the way identical as early invasive cancer in the high risk. Arguments for the treatment of ductal carcinoma in situ in the same way as patients with early invasive cancer have been presented. These argu­ments comprise: unknown natural history of untreated DCIS, high risk of undervaluation of the invasive component in the core-needle biopsy, the increase of recurrence risk with the progress of time, lack of verified separators of the groups with the risk of adverse course of the disease, the results of the clinical studies confirming the justification of combined local treatment and the proof that the clinical course of DCIS is the same as early invasive breast cancer, and, first and foremost, the fact that there are no clinical studies which could justify a limitation of the treatment scope.

Abstract

Heterogenicity of breast ductal carcinoma in situ gives rise to opposing proposals concerning its treatment — ranging from attempts to recommend the watch and wait strategy in low risk forms ending with the currently binding stan­dards of treatment of DCIS in the way identical as early invasive cancer in the high risk. Arguments for the treatment of ductal carcinoma in situ in the same way as patients with early invasive cancer have been presented. These argu­ments comprise: unknown natural history of untreated DCIS, high risk of undervaluation of the invasive component in the core-needle biopsy, the increase of recurrence risk with the progress of time, lack of verified separators of the groups with the risk of adverse course of the disease, the results of the clinical studies confirming the justification of combined local treatment and the proof that the clinical course of DCIS is the same as early invasive breast cancer, and, first and foremost, the fact that there are no clinical studies which could justify a limitation of the treatment scope.

Get Citation

Keywords

DCIS — breast ductal carcinoma in situ, cancer heterogenicity, local treatment, watch and wait strategy, clinical studies

About this article
Title

Should local treatment of breast ductal carcinoma in situ be the same as the treatment of early invasive breast cancer

Journal

Nowotwory. Journal of Oncology

Issue

Vol 67, No 1 (2017)

Article type

Other materials agreed with the Editors

Pages

74-78

Published online

2017-08-24

DOI

10.5603/NJO.2017.0012

Bibliographic record

Nowotwory. Journal of Oncology 2017;67(1):74-78.

Keywords

DCIS — breast ductal carcinoma in situ
cancer heterogenicity
local treatment
watch and wait strategy
clinical studies

Authors

Sylwia Grodecka-Gazdecka

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest VM Media sp. z o.o. VM Group sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl